Uno studio per conoscere il farmaco di studio denominato PF-08634404 in combinazione con la chemioterapia nel cancro gastroesofageo
UNO STUDIO INTERVENTISTICO DI FASE 2/3 DI PF-08634404 IN COMBINAZIONE CON CHEMIOTERAPIA IN PARTECIPANTI NAÏVE AL TRATTAMENTO CON ADENOCARCINOMA GASTRICO, DELLA GIUNZIONE GASTROESOFAGEA O DELL'ESOFAGO LOCALMENTE AVANZATO O METASTATICO
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Pfizer CT.gov Call Center
- Numero di telefono: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Luoghi di studio
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Non ancora reclutamento
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510655
- Reclutamento
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, Cina, 430079
- Reclutamento
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200031
- Reclutamento
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- Reclutamento
- Sichuan Cancer hospital
-
-
-
-
-
Paris, Francia, 75015
- Reclutamento
- Hôpital Européen Georges Pompidou
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 464-8681
- Reclutamento
- Aichi Cancer Center
-
-
-
-
Central District
-
Petah Tikva, Central District, Israele, 4941492
- Reclutamento
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israele, 5265601
- Reclutamento
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, Israele, 6423906
- Reclutamento
- Sourasky Medical Center
-
-
-
-
-
Milan, Italia, 20141
- Reclutamento
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
-
Bayamón, Porto Rico, 00959
- Reclutamento
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, Porto Rico, 00674
- Reclutamento
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spagna, 08035
- Reclutamento
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], Spagna, 32005
- Non ancora reclutamento
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
California
-
Atascadero, California, Stati Uniti, 93422
- Reclutamento
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, Stati Uniti, 91505
- Reclutamento
- UCLA Hematology/Oncology - Burbank
-
Encino, California, Stati Uniti, 91436
- Reclutamento
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, Stati Uniti, 90292
- Reclutamento
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, Stati Uniti, 91326
- Reclutamento
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, Stati Uniti, 94158
- Non ancora reclutamento
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, Stati Uniti, 94158
- Non ancora reclutamento
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, Stati Uniti, 93401
- Reclutamento
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, Stati Uniti, 93101
- Reclutamento
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, Stati Uniti, 90404
- Reclutamento
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, Stati Uniti, 80303
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, Stati Uniti, 80112
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Stati Uniti, 80907
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Stati Uniti, 80923
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Stati Uniti, 80218
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Stati Uniti, 80220
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, Stati Uniti, 80113
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, Stati Uniti, 80228
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, Stati Uniti, 80120
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, Stati Uniti, 80124
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, Stati Uniti, 80504
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, Stati Uniti, 81003
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, Stati Uniti, 80260
- Reclutamento
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, Stati Uniti, 32117
- Non ancora reclutamento
- Florida Cancer Specialists
-
Fleming Island, Florida, Stati Uniti, 32003
- Non ancora reclutamento
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, Stati Uniti, 33410
- Non ancora reclutamento
- Florida Cancer Specialists
-
Sebring, Florida, Stati Uniti, 33870
- Non ancora reclutamento
- Florida Cancer Specialists
-
Wellington, Florida, Stati Uniti, 33414
- Non ancora reclutamento
- Florida Cancer Specialists
-
West Palm Beach, Florida, Stati Uniti, 33401
- Non ancora reclutamento
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, Stati Uniti, 60005
- Reclutamento
- Illinois Cancer Specialists
-
Bloomington, Illinois, Stati Uniti, 61704
- Reclutamento
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, Stati Uniti, 60631
- Reclutamento
- Illinois Cancer Specialists
-
Galesburg, Illinois, Stati Uniti, 61401
- Reclutamento
- Illinois CancerCare - Galesburg
-
Niles, Illinois, Stati Uniti, 60714
- Reclutamento
- Illinois Cancer Specialists
-
Ottawa, Illinois, Stati Uniti, 61350
- Reclutamento
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, Stati Uniti, 61554
- Reclutamento
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stati Uniti, 61615
- Reclutamento
- Illinois CancerCare, P.C.
-
Peru, Illinois, Stati Uniti, 61354
- Reclutamento
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, Stati Uniti, 61571
- Reclutamento
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, Stati Uniti, 21401
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, Stati Uniti, 20817
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, Stati Uniti, 20613
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, Stati Uniti, 21044
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, Stati Uniti, 20876
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, Stati Uniti, 20774
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, Stati Uniti, 20850
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, Stati Uniti, 20904
- Reclutamento
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, Stati Uniti, 89502
- Reclutamento
- Renown Regional Medical Center
-
Reno, Nevada, Stati Uniti, 89502
- Reclutamento
- Renown Health Medical Oncology
-
Reno, Nevada, Stati Uniti, 89502
- Reclutamento
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, Stati Uniti, 07960
- Non ancora reclutamento
- Atlantic Health System
-
Summit, New Jersey, Stati Uniti, 07901
- Non ancora reclutamento
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, Stati Uniti, 11101
- Reclutamento
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, Stati Uniti, 11101
- Reclutamento
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, Stati Uniti, 10021
- Reclutamento
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, Stati Uniti, 10022
- Reclutamento
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45245
- Reclutamento
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Stati Uniti, 45242
- Reclutamento
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Stati Uniti, 45211
- Reclutamento
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, Stati Uniti, 45014
- Reclutamento
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, Stati Uniti, 19020
- Reclutamento
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, Stati Uniti, 18901
- Reclutamento
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, Stati Uniti, 19044
- Reclutamento
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, Stati Uniti, 19047
- Reclutamento
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, Stati Uniti, 19063
- Reclutamento
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, Stati Uniti, 18960
- Reclutamento
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, Stati Uniti, 19096
- Reclutamento
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, Stati Uniti, 75063
- Reclutamento
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, Stati Uniti, 22201
- Reclutamento
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, Stati Uniti, 23320
- Reclutamento
- Virginia Oncology Associates
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, Stati Uniti, 23666
- Reclutamento
- Virginia Oncology Associates
-
Manassas, Virginia, Stati Uniti, 20110
- Reclutamento
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, Stati Uniti, 23606
- Reclutamento
- Virginia Oncology Associates
-
Norfolk, Virginia, Stati Uniti, 23502
- Reclutamento
- Virginia Oncology Associates
-
Reston, Virginia, Stati Uniti, 20190
- Reclutamento
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, Stati Uniti, 23456
- Reclutamento
- Virginia Oncology Associates
-
Woodbridge, Virginia, Stati Uniti, 22191
- Reclutamento
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- Reclutamento
- University of Washington Medical Center
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Stati Uniti, 98104
- Reclutamento
- Harborview Medical Center
-
-
-
-
-
Tainan, Taiwan, 704302
- Reclutamento
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Reclutamento
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Reclutamento
- Taipei Veterans General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Altri nomi:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Sperimentale: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Altri nomi:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Comparatore attivo: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Lasso di tempo: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
Lasso di tempo: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fase 2: Incidenza di Anticorpi Anti-Farmaco (ADA) contro PF-08634404
Lasso di tempo: Circa 21 mesi
|
Circa 21 mesi
|
|
|
Fase 3: Incidenza di ADA contro PF-08634404
Lasso di tempo: Circa 21 mesi
|
Circa 21 mesi
|
|
|
Fase 3: Variazione rispetto al basale del punteggio totale del Functional Assessment of Cancer Therapy - Gastric (FACT-Ga)
Lasso di tempo: Circa 4 anni
|
Circa 4 anni
|
|
|
Fase 3: Tempo fino al deterioramento definitivo nel punteggio totale FACT-Ga
Lasso di tempo: Circa 4 anni
|
Circa 4 anni
|
|
|
Fase 3: Tempo fino al deterioramento definitivo nel punteggio della sottoscala del cancro gastrico (GaCS)
Lasso di tempo: Circa 4 anni
|
Circa 4 anni
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
Lasso di tempo: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
Lasso di tempo: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Lasso di tempo: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Lasso di tempo: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Lasso di tempo: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
Lasso di tempo: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Pfizer CT.gov Call Center, Pfizer
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Neoplasie allo stomaco
- Adenocarcinoma dell'esofago
- Aminoacidi, peptidi e proteine
- Proteine
- Terapie
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Nivolumab
- Terapia farmacologica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- C6461016
- 2025-524717-86-00 (Identificatore di registro: CTIS (EU))
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .